Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03264404 · ClinicalTrials.gov registry record · Phase 2
Azacitidine and Pembrolizumab in Pancreatic Cancer
A Phase 2 study, sponsored by Susan E. Bates.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03264404 is a Phase 2 study that has completed, run by Susan E. Bates. The registered enrollment target is 36 participants.
The verdict
NCT03264404, a Phase 2 study, has completed, sponsored by Susan E. Bates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of combining immune therapy, pembrolizumab, with a hypomethylating agent, azacitidine, for pancreatic cancer. People who have advanced pancreatic cancer with disease progression on first-line therapy are usually treated with a second chemotherapy regimen. However, there is no single accepted chemotherapy regimen and national guidelines recommend chemotherapy or clinical trial participation. In this study, all study subjects will receive a combination of immune therapy (every 3 weeks) and a hypomethylating agent (every 4 weeks). To date, studies have shown that combining a hypomethylating agent with chemotherapy or immune therapy may benefit patients across different solid tumor types including pancreatic cancer. Preclinical data in a mouse model of pancreatic cancer demonstrates improvement in survival with the combination of a hypomethylating agent and immune therapy. However, the use of single agent hypomethylating agent or immune therapy has not been shown to be effective in patients with pancreatic cancer. The one exception, to date, is the use of immune therapy in those individuals with a particular genetic feature known as mismatch repair deficiency and microsatellite instability. The combination of immune therapy and a hypomethylating agent has not been studied in human subjects and is not approved by the FDA for use in pancreatic cancer. This is a non-randomized, single-center, open-label trial of pembrolizumab and azacitidine in subjects with locally advanced or metastatic pancreatic adenocarcinoma. Approximately 31 individuals will be asked to participate in this study.
Interventions
- DRUG Pembrolizumab
- DRUG Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2024-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03264404
The ClinicalTrials.gov registry entry for NCT03264404 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Susan E. Bates, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03264404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03264404 about?
NCT03264404 is a clinical study titled "Azacitidine and Pembrolizumab in Pancreatic Cancer". The purpose of this study is to determine the effectiveness of combining immune therapy, pembrolizumab, with a hypomethylating agent, azacitidine, for pancreatic cancer. People who have advanced pancreatic cancer with disease progression on first-line therapy are usually treated with a second chemot...
What is the current status of trial NCT03264404?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-10-01. Estimated completion is 2024-12-03.
What interventions are being tested in trial NCT03264404?
The interventions under investigation include: Pembrolizumab (DRUG), Azacitidine (DRUG).
Who is sponsoring clinical trial NCT03264404?
This trial is sponsored by Susan E. Bates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.